FIELD: medicine.
SUBSTANCE: present invention relates to a compound represented by one of following isomeric structures Ia and Ib, which is used for the treatment of prevention of diseases related to protein aggregation, to a pharmaceutical composition based on it, to a method for the treatment or prevention of diseases related to protein aggregation using the claimed compound, as well as to the use of the claimed compound or the composition based on it for the production of a drug:
, where Y is N, and Z is -CH-; where either X is 
, and Hal is halogen selected from chlorine or bromine, or X is 
, and Hal is bromine; where each R is independently hydrogen or cation selected from sodium, lithium, potassium, ammonium or a protonated form of ethanolamine, choline, lysine, meglumine, piperazine and tromethamine.
EFFECT: obtaining a compound for the treatment or prevention of a disease related to protein aggregation.
16 cl, 4 dwg, 12 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NOVEL COMPOUNDS FOR DIAGNOSING, TREATING AND PREVENTING DISEASES ASSOCIATED WITH ALPHA-SYNUCLEIN AGGREGATION | 2020 |
|
RU2822486C1 |
| NEW DRUG PREPARATION FOR INHIBITING AGGREGATION OF PROTEINS INVOLVED IN DISEASES RELATED TO AGGREGATION OF PROTEINS, AND NEURODEGENERATIVE DISEASES | 2009 |
|
RU2531915C2 |
| SELECTIVE BUTYRYLCHOLIN ESTERASE INHIBITORS | 2005 |
|
RU2386627C2 |
| SILICON-CONTAINING IVACAFTOR ANALOGUES | 2017 |
|
RU2796112C2 |
| TACRINE DERIVATIVES AS ACETYLCHOLINESTERASE INHIBITORS | 2004 |
|
RU2402545C2 |
| N-(2-THIAZOLYL)AMIDE DERIVATIVES AS GSK-3 INHIBITORS | 2007 |
|
RU2429237C2 |
| SEPARATION OF ENANTIOMERS OF 3-ETHYLBICYCLO [3_2_0] HEPT-3-EN-6-ONE | 2016 |
|
RU2734475C2 |
| CHROMON OXIME NEW DERIVATIVE AND ITS USE AS ALLOSTERIC MODULATOR OF METABOTROPIC GLUTAMATE RECEPTORS | 2015 |
|
RU2672569C2 |
| GLYCOSIDASE INHIBITORS AND THEIR APPLICATIONS | 2013 |
|
RU2672873C2 |
| COMPOUNDS FOR IMAGING OF TAU PROTEIN AGGREGATES | 2017 |
|
RU2778739C2 |
